Key TakeawaysOncology maintains the largest share of trial activity, enabled by deeper biomarker understanding and sustained investment despite ongoing gaps in high-need subtypes.Phase II attrition declined to 26% from 31% in 2024, yet persistent early stoppage continues to pressure Phase III throughput and ROI.US leadership in recruiting sites is tempered by uneven competition, with prominent […]
